OakChart

Biodesix Inc

BDSXHealthcare·Diagnostics & Research·USA·Micro·NASD·Nov 11 • 3:59 PM ET

10.12+0.10 (1.00%)
2026-11-12 02:02 CET
Market cap
111.11 USD m
Revenue, TTM
105.21 USD m
Net income, TTM
-27.08 USD m
Free cash flow, TTM
-19.14 USD m
EPS diluted, TTM
-2.76
P/E
-
Compare

Price

BDSX against its 20, 50 and 200-day averages
2050200beatmiss
10.0020.0030.00795K1.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BDSXclose 10.1220-day 20.1050-day 24.57200-day 18.8910.1252w high

68.3% under the 52-week high of 31.97 on 28 Sep 2026. 52-week low 5.26 on 9 Jan 2026. Last 15 sessions, 225.5% high to low

Volume 3.81× normal · the line is the 50-bar volume average

Profile

BDSX
52-week range, 18% of the way up
5.2631.97

Biodesix, Inc. operates as a diagnostic solutions company. It engages in providing blood-based diagnostic tests and development services. The firm offers five diagnostic tests, including Nodify CDT, Nodify XL2, GeneStrat ddPCR, GeneStrat NGS, and VeriStrat. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Employees334
IPOOct 28, 2020
Beta0.71
ATR, 14d2.52
Rel volume3.81
Short float4.26%
Insider own55.58%
Inst own39.46%

Snapshot

6 groups

Valuation

Index-
Market Cap112.22M
Enterprise Value156.15M
Income-27.08M
Sales105.21M
Book/sh0.78
Cash/sh2.57
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees334
IPOOct 28, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S1.07
P/B12.90
P/C3.94
P/FCF-
EV/EBITDA-
EV/Sales1.48
Quick Ratio2.87
Current Ratio2.96
Debt/Eq8.35
LT Debt/Eq8.09
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.76
EPS next Y-1.85
EPS next Q-0.63
EPS this Y38.03%
EPS next Y35.97%
EPS next 5Y40.04%
EPS past 3/5Y46.84% 27.68%
Sales past 3/5Y32.31% 14.20%
EPS Y/Y TTM48.56%
Sales Y/Y TTM31.23%
EPS Q/Q35.16%
Sales Q/Q10.44%
EarningsNov 05 AMC
EPS/Sales Surpr.-0.27% -12.52%

Ownership

Insider Own55.58%
Insider Trans0.70%
Inst Own39.46%
Inst Trans3.93%
ROA-29.65%
ROE-778.89%
ROIC-34.31%
Gross Margin81.16%
Oper. Margin-18.68%
Profit Margin-25.74%
SMA20-49.64%
SMA50-58.82%
SMA200-46.42%
Trades-

Technical

Shs Outstand11.05M
Shs Float4.93M
Short Float4.26%
Short Ratio1.43
Short Interest0.21M
52W High31.97 -68.35%
52W Low5.26 92.40%
Volatility29.45% 13.26%
ATR (14)2.52
RSI (14)24.25
Beta0.71
Rel Volume3.81
Avg Volume147.05K
Volume560,477

Performance

Perf Week-52.91%
Perf Month-59.52%
Perf Quarter-57.46%
Perf Half Y-30.87%
Perf YTD48.82%
Perf Year21.34%
Perf 3Y-57.83%
Perf 5Y-93.59%
Perf 10Y-
Recom1.00
Target Price33.83
Prev Close10.02
Price10.12
Change %1.00%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Jun 25, 2026InitiatedRRoth CapitalBuy$32+216.2%
Jun 15, 2026InitiatedHH.C. WainwrightBuy$26+156.9%
Feb 27, 2026UpgradeWWilliam BlairMkt Perform → Outperform
May 14, 2025DowngradeWWilliam BlairOutperform → Mkt Perform
Sep 16, 2024InitiatedBScotiabankSector Outperform
Jul 26, 2024InitiatedCCraig HallumBuy$3-70.4%
May 13, 2024InitiatedTTD CowenBuy$2.80-72.3%
May 03, 2024InitiatedLLake StreetBuy$3-70.4%
Nov 17, 2021DowngradeMMorgan StanleyOverweight → Equal-Weight$21 → $11+8.7%
Nov 23, 2020InitiatedWWilliam BlairOutperform

Peers

Mkt cap
TickerCompanyMkt cap
VCYTVeracyte Inc2.03B
BIAFBioAffinity Technologies Inc4.41M
GHGuardant Health Inc20.94B
NEONeogenomics Inc2.18B
CSTLCastle Biosciences Inc1.05B
XGNExagen Inc121.98M
IMDXInsight Molecular Diagnostics Inc78.21M
GRALGRAIL Inc5.65B
MDXHMDxHealth SA13.98M
QTRXQuanterix Corp143.39M

Insider trading

latest 14 of 22
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
SCHULER JACK WEmeritus DirectorAug 12 '26Buy24.4715,000366,992555,810Aug 13 05:22 PM
SCHULER JACK WEmeritus DirectorAug 10 '26Buy24.2513,900337,029527,110Aug 12 05:55 PM
SCHULER JACK WEmeritus DirectorAug 11 '26Buy24.0113,700328,911540,810Aug 12 05:55 PM
Pestano Gary AnthonyChief Development OfficerFeb 23 '26Sale12.785567,10310,359Feb 23 08:22 PM
O'Kane KieranChief Commercial OfficerFeb 23 '26Sale12.785356,8359,819Feb 23 08:22 PM
Cowie Robin HarperCFO, Sec'y & TreasurerFeb 23 '26Sale12.785356,83516,231Feb 23 08:22 PM
Vazquez ChrisChief Accounting OfficerFeb 23 '26Sale12.782112,6961,586Feb 23 08:22 PM
Hutton ScottPresident & CEOFeb 23 '26Sale12.781,49019,03648,767Feb 23 08:22 PM
Hutton ScottOfficerFeb 23 '26Proposed Sale12.771,49019,027Feb 23 08:22 PM
O'Kane KieranChief Commercial OfficerFeb 10 '26Sale10.085845,8898,885Feb 11 06:03 PM
Vazquez ChrisChief Accounting OfficerFeb 10 '26Sale10.081011,0181,234Feb 11 06:03 PM
Hutton ScottPresident & CEOFeb 10 '26Sale10.083,55935,88945,413Feb 11 06:03 PM
Cowie Robin HarperCFO, Sec'y & TreasurerFeb 10 '26Sale10.089419,48915,297Feb 11 06:03 PM
Pestano Gary AnthonyChief Development OfficerFeb 10 '26Sale10.085405,4459,387Feb 11 06:03 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M
GNMXCorgi Genomics & Precision Medicine ETFAUM: 1.28M

News

latest 14 of 200
  • Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting (GlobeNewswire) +21.22%
  • Biodesix Breaks Its Beat-And-Raise Streak As Growth Slows To 10% And Guidance Falls Below The Original Outlook (Earnings Whispers) -7.68% -57.01%
  • Biodesix Announces Third Quarter 2026 Results and Highlights (GlobeNewswire)
  • Biodesix to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Biodesix Must Show Its Lung Nodule Test Surge Can Outrun A Shrinking Pharma Backlog (Earnings Whispers) +8.14%
  • Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026 (GlobeNewswire)
  • American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification (GlobeNewswire)
  • Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers (GlobeNewswire)
  • Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung Testing into Routine Lung Nodule Care at CHEST 2026 (GlobeNewswire)
  • Biodesix Advances MRD Monitoring Programs With Bio-Rad and Thermo Fisher (InvestorsHub)
  • Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring (GlobeNewswire)
  • Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings (GlobeNewswire)
  • Biodesix to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Biodesix Inc (BDSX) (Q2 2026) Earnings Call Highlights: Revenue Surges 34% on Strong Diagnostic ... (GuruFocus.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.750-0.748-0.75024.0427.487
2026Q22026-08-05-0.710-0.902-0.70626.8626.037
2026Q12026-05-04-0.810-1.130-0.80725.5623.125
2025Q42026-02-26-0.490-0.860-0.49428.7625.734
2025Q32025-11-03-1.160-1.490-1.16221.7720.975
2025Q22025-08-07-1.600-1.378-1.56420.0218.575
2025Q12025-05-13-1.600-1.396-1.51517.9619.426
2024Q42025-03-03-1.200-1.344-1.12620.4319.886
2024Q32024-11-01-1.400-1.462-1.40218.1518.576
2024Q22024-08-07-1.600-1.842-1.70017.9016.135
2024Q12024-05-08-2.800-2.842-2.80214.8214.183
2023Q42024-03-01-2.000-2.182-1.98014.6715.623
2023Q32023-11-07-2.800-2.934-2.74713.4914.123
2023Q22023-08-07-3.400-4.124-3.40311.8711.673
2023Q12023-05-11-4.800-4.734-4.8109.068.713
2022Q42023-03-06-7.000-5.552-7.0369.6110.774

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-77.100-25.596-23.60645.5833.42
2021FY-31.600-31.544-31.54354.5154.68
2022FY-31.000-28.898-31.08938.2139.31
2023FY-12.800-13.114-12.70149.0950.14
2024FY-6.600-6.964-6.62271.3270.77
2025FY-4.670-5.148-4.67088.5086.02
2026FY--2.894--104.92
2027FY--1.853--127.39
2028FY--1.007--150.57
2029FY--0.340--176.5
2030FY-0.240--201.5

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0970527.3725.1032.80
2026Q4S2026-11-0670428.2625.1032.80
2026Q4S2026-11-0570131.9231.5032.80
2026Q4S2026-10-2670131.9231.5032.80
2026Q4S2026-10-2070031.9931.5032.80
2026Q4S2026-10-1673131.9931.5032.80
2026Q4S2026-08-0773131.9931.5032.80
2026Q4S2026-08-0673131.9931.5032.80
2026Q4S2026-07-1970031.8231.0332.70
2026Q4S2026-07-1471031.8231.0332.70
2026Q4S2026-07-1071031.8531.0332.90
2026Q4S2026-06-2471031.8531.0332.90
2026Q4S2026-06-2371131.8531.0332.90
2026Q4S2026-06-1261131.7931.0332.90

Estimate history

EPS, annual-19.717-2410.658-23.606-31.543-31.089-12.701-6.622-4.67-2.7604
Period20182019202020212022202320242025TTM
EPS, quarterly-1.402-1.126-1.515-1.564-1.162-0.494-0.807-0.706-0.754
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual20.43224.55245.55754.50638.21249.08771.32388.499105.21
Period20182019202020212022202320242025TTM
Sales, quarterly18.15120.42917.95820.01821.76828.75525.55526.86124.041
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.3270.0131.3281.5393.8814.8127.2758.25311.055
Period20182019202020212022202320242025MRQ
Shares, quarterly7.2737.2757.3227.3297.9558.25310.10710.5511.055
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue105.2188.5071.3249.0938.2154.5145.5624.5520.43
Cost of Goods Sold Incl. D&A19.8221.9120.9315.8817.1633.0824.538.674.41
Gross Profit85.3966.5950.3933.2121.0521.4321.0315.8816.03
Selling, General and Administrative Excl. Other105.0594.3684.6574.5171.5660.7543.1538.5134.09
Research and Development12.2812.009.569.9913.1012.7910.8210.478.19
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-19.65-27.77-34.26-41.30-50.51-39.32-22.12-22.63-18.06
Interest Expense8.027.727.129.548.074.517.603.012.92
Unusual Expense0.020.391.621.326.98-0.682.076.225.51
Net Income Before Taxes-27.08-35.27-42.93-52.15-65.45-43.16-31.35-30.73-26.17
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-27.08-35.27-42.93-52.15-65.45-43.16-31.35-30.73-26.17
Net Income From Continuing Operations-27.08-35.27-42.93-52.15-65.45-43.16-31.35-30.73-26.17
Net Income-27.08-35.27-42.93-52.15-65.45-43.16-31.35-30.73-26.17
EPS (Recurring)-2.54-4.63-6.45-12.48-28.77-31.89-22.51-2,069.17-16.81
EPS (Basic, Before Extraordinaries)-2.76-4.67-6.62-12.70-31.09-31.54-23.61-2,410.66-19.72
EPS (Diluted)-2.76-4.67-6.62-12.70-31.09-31.54-23.61-2,410.66-19.72
EBITDA-14.02-22.16-28.80-35.79-46.91-36.14-19.21-19.83-16.32
Non-Operating Income (Expense)0.610.600.070.010.11-0.010.441.130.33
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.864.146.645.374.714.943.710.170.14
Price To Sales Ratio3.020.582.783.082.532.6611.75--
Gross Margin81.1675.2570.6567.6655.1039.3146.1664.6978.44
Operating Margin-18.68-31.37-48.03-84.13-132.17-72.14-48.55-92.16-88.40
Net Margin-25.74-39.85-60.19-106.23-171.27-79.18-68.81-125.15-128.06
Shares Outstanding11.058.257.274.813.881.541.330.011.33
Market Capitalization111.11111.11222.60162.5094.73162.88535.48500.83-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue24.0426.8625.5528.7521.7720.0217.9620.43
Cost of Goods Sold Incl. D&A5.914.824.214.884.114.033.704.34
Gross Profit18.1322.0421.3523.8817.6615.9914.2616.09
Selling, General and Administrative Excl. Other24.2427.4227.5525.8424.7125.6823.3222.63
Research and Development2.993.133.292.872.993.272.872.41
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.11-5.38-6.20-1.97-7.04-9.69-9.06-6.55
Interest Expense2.001.981.982.062.071.901.691.75
Unusual Expense0.000.010.010.000.01-0.070.450.10
Net Income Before Taxes-8.03-7.27-7.79-3.98-8.72-11.47-11.10-8.25
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-8.03-7.27-7.79-3.98-8.72-11.47-11.10-8.25
Net Income From Continuing Operations-8.03-7.27-7.79-3.98-8.72-11.47-11.10-8.25
Net Income-8.03-7.27-7.79-3.98-8.72-11.47-11.10-8.25
EPS (Recurring)-0.75-0.71-0.81-0.49-1.16-1.57-1.47-1.12
EPS (Basic, Before Extraordinaries)-0.75-0.71-0.81-0.49-1.16-1.56-1.51-1.13
EPS (Diluted)-0.75-0.71-0.81-0.49-1.16-1.56-1.51-1.13
EBITDA-4.71-3.96-4.78-0.56-5.67-8.28-7.66-5.15
Non-Operating Income (Expense)0.080.100.390.050.410.050.100.15
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.850.821.111.071.051.040.971.26
Price To Sales Ratio3.022.261.460.620.710.541.233.14
Gross Margin75.4082.0683.5583.0381.1479.8679.3878.75
Operating Margin-25.42-20.01-24.25-6.84-32.36-48.42-50.47-32.04
Net Margin-33.41-27.08-30.50-13.84-40.04-57.29-61.82-40.39
Shares Outstanding11.0510.5510.118.257.957.337.327.27
Market Capitalization112.22233.52142.9554.1060.4041.3791.56222.60

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments19.0926.3426.3843.1932.8162.335.496.11
Short Term Receivables9.048.607.685.073.6615.305.291.89
Inventories1.301.001.401.402.903.200.800.70
Other Current Assets3.103.544.223.684.255.311.121.21
Total Current Assets32.5239.4839.6853.3343.6186.1412.709.91
Net Property, Plant & Equipment30.8131.8029.618.824.183.182.121.39
Total Investments and Advances0.000.000.000.000.000.000.000.00
Intangible Assets18.9120.9122.9424.8326.6528.2930.1227.66
Deferred Tax Assets2.201.93------
Other Assets5.235.066.865.921.663.460.090.10
Total Assets89.6799.1899.1092.9176.10121.0745.0339.06
Short Term Debt Incl. Current Port. of LT Debt1.370.740.301.590.0211.8412.160.00
Accounts Payable3.082.192.931.691.668.961.720.89
Other Current Liabilities12.9911.3830.1819.5627.2811.328.723.58
Total Current Liabilities17.4414.3233.4222.8428.9632.1222.604.47
Long Term Debt71.4861.2460.3930.269.9915.9323.8123.10
Provision for Risks Charges0.000.000.000.000.000.000.330.27
Deferred Tax Liabilities2.201.93------
Other Liabilities1.020.810.7119.2017.4231.8529.4725.29
Total Liabilities92.1478.3094.5272.3056.3779.9076.2153.12
Non-Equity Reserves0.000.000.000.000.000.00193.96183.96
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity-2.4620.884.5820.6119.7341.17-225.14-198.03
Total Shareholders Equity-2.4620.884.5820.6119.7341.17-225.14-198.03
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity-2.4620.884.5820.6119.7341.17-225.14-198.03
Total Liabilities & Stockholders Equity89.6799.1899.1092.9176.10121.0745.0339.06
Book Value Per Share-0.302.870.955.3112.8131.00-17,663.64-149.22
Tangible Book Value Per Share-2.59-0.00-3.82-1.09-4.509.69-20,026.99-170.06
Full-Time Employees334273217245218200--
Price to Book Ratio12.7710.66-112.38-32.638.2613.01-1.96-
Return on Assets-37.35-43.30-54.32-77.45-43.78-38.54-73.08-
Return on Equity-383.09-337.30-414.09-324.53-141.75---
Return on Invested Capital-51.09-52.28-80.26-128.67-145.22-54.91--
Quick Ratio1.792.691.152.271.412.580.532.06
Current Ratio1.862.761.192.341.512.680.562.22

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-27.08-35.27-42.93-52.15-65.45-43.16-31.35-30.73-26.17
Depreciation5.625.605.465.513.603.182.902.791.74
Other Funds (Non Cash)5.586.0310.4512.4621.227.1711.887.856.50
Funds from Operations-15.88-23.64-27.02-34.17-40.63-32.81-16.57-20.08-17.93
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.350.33-21.6711.30-4.344.59-4.80-1.650.25
Cash from Operating Activities-18.22-23.30-48.69-22.87-44.97-28.22-21.37-21.73-17.68
Capital Expenditures-1.10-0.40-3.44-23.06-3.53-2.55-2.18-1.42-0.62
Net Assets From Acquisitions0.000.000.000.000.000.00-0.75-0.460.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-1.10-0.40-3.44-23.06-3.53-2.55-2.93-1.87-0.62
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock32.197.2952.5928.8660.0317.4473.3410.0531.55
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock32.197.2952.5928.8660.0317.4473.3410.0531.55
Proceedsfrom Stock Options31.466.7951.9428.1359.4116.6772.0010.0031.50
Issuance or Reduction of Debt, Net0.029.98-0.059.049.70-16.187.8013.04-12.65
Change in Long Term Debt0.029.98-0.059.049.70-16.187.8013.04-12.65
Issuance of Long Term Debt0.0310.000.009.0938.3129.257.8013.049.87
Reduction of Long Term Debt-0.01-0.02-0.05-0.05-28.60-45.430.000.00-22.52
Net Financing Active Other Cash Flow-1.08-0.82-0.45-8.77-10.860.00-0.01-0.120.13
Other Financing Activities Uses-1.08-0.82-0.45-8.77-10.860.00-0.01-0.120.00
Cash from Financing Activities31.1316.4552.0929.1358.881.2681.1322.9719.03
Net Change in Cash11.80-7.26-0.04-16.8010.38-29.5156.84-0.630.74
Free Cash Flow-19.14-23.56-51.92-45.79-48.27-30.46-23.31-23.04-18.18
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments28.5130.1025.6719.0916.7020.83
Short Term Receivables9.129.119.509.0412.677.45
Inventories1.201.201.501.301.401.60
Other Current Assets3.313.164.243.102.622.57
Total Current Assets42.1343.5640.9132.5233.4032.45
Net Property, Plant & Equipment30.1529.6430.0830.8130.7030.34
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets17.5618.0118.4818.9119.4119.90
Deferred Tax Assets---2.20--
Other Assets4.104.115.165.235.215.05
Total Assets93.9495.3394.6489.6788.7287.74
Short Term Debt Incl. Current Port. of LT Debt2.201.611.451.371.411.25
Accounts Payable2.632.163.653.083.622.97
Other Current Liabilities9.4211.529.3812.9913.1310.94
Total Current Liabilities14.2515.2914.4917.4418.1515.16
Long Term Debt70.2470.1970.1671.4871.5270.89
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---2.20--
Other Liabilities0.780.700.861.020.770.55
Total Liabilities85.2786.1885.5092.1490.4486.60
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity8.689.149.13-2.46-1.721.14
Total Shareholders Equity8.689.149.13-2.46-1.721.14
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity8.689.149.13-2.46-1.721.14
Total Liabilities & Stockholders Equity93.9495.3394.6489.6788.7287.74
Book Value Per Share0.780.870.90-0.30-0.220.16
Tangible Book Value Per Share-0.80-0.84-0.93-2.59-2.66-2.56
Full-Time Employees---334--
Price to Book Ratio12.9024.96-48.55-31.4148.6236.35
Return on Assets-29.65-30.33-35.34-37.35-41.30-40.36
Return on Equity-778.89-540.01-316.53-383.09-302.55-219.68
Return on Invested Capital-10.18-9.17-9.83-5.77-12.49-15.92
Quick Ratio2.872.772.721.791.762.03
Current Ratio2.962.852.821.861.842.14

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-8.03-7.27-7.79-3.98-8.72-11.47
Depreciation1.391.411.421.411.381.41
Other Funds (Non Cash)1.391.221.501.481.401.33
Funds from Operations-5.26-4.64-4.88-1.10-5.94-8.73
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.953.04-5.291.84-2.942.17
Cash from Operating Activities-7.20-1.60-10.170.75-8.88-6.56
Capital Expenditures-0.60-0.25-0.14-0.10-0.07-0.10
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.60-0.25-0.14-0.10-0.07-0.10
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock6.726.4117.091.985.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock6.726.4117.091.985.000.00
Proceedsfrom Stock Options6.366.4016.731.984.810.00
Issuance or Reduction of Debt, Net0.00-0.00-0.010.03-0.019.97
Change in Long Term Debt0.00-0.00-0.010.03-0.019.97
Issuance of Long Term Debt0.000.000.000.03-0.009.97
Reduction of Long Term Debt0.00-0.00-0.01-0.01-0.00-0.01
Net Financing Active Other Cash Flow-0.51-0.15-0.16-0.26-0.17-0.19
Other Financing Activities Uses-0.51-0.15-0.16-0.26-0.17-0.19
Cash from Financing Activities6.226.2816.901.744.829.78
Net Change in Cash-1.594.426.582.38-4.123.13
Free Cash Flow-7.76-1.80-10.250.66-8.93-6.61

Revenue breakdown

Development Services2024: 6.62M 2025: 9.30M
Diagnostic Tests2024: 64.71M 2025: 79.20M
United States2024: 71.32M 2025: 88.50M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.26%0.2M4.9M103.69K
2026-10-154.47%0.2M4.7M99.36K
2026-09-304.30%0.2M4.7M97.43K
2026-09-154.56%0.2M4.7M99.44K
2026-08-313.61%0.2M6.1M94.36K
2026-08-143.20%0.2M4.7M73.78K
2026-07-313.32%0.2M4.7M75.67K
2026-07-153.60%0.2M4.7M75.83K
2026-06-302.26%0.1M4.7M71.79K
2026-06-152.25%0.1M4.7M65.03K
2026-05-291.82%0.1M5.9M87.61K
2026-05-153.02%0.1M4.6M101.07K
2026-04-303.62%0.1M4.1M105.65K
2026-04-154.41%0.2M4.0M166.24K
2026-03-314.71%0.2M3.9M1.47M
2026-03-134.64%0.2M3.9M1.47M
2026-02-275.76%0.2M3.9M1.42M
2026-02-137.66%0.2M3.1M1.41M
2026-01-307.97%0.2M3.1M1.41M
2026-01-1514.61%0.5M3.3M1.40M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-058-KCurrent report2026-11-02SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-18SCHEDULE 13GSEC
2026-06-01424B3SEC
2026-05-29EFFECTEffectiveness filing by commission orderSEC
2026-05-27CORRESPSEC
2026-05-26UPLOADUpload SubmissionSEC
2026-05-21S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-208-KCurrent report2026-05-19SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-08SCHEDULE 13G/ASEC
2026-05-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-048-KCurrent report2026-05-04SEC
2026-04-28SCHEDULE 13GSEC
2026-04-09ARSAnnual report to security holders. 2025-12-31SEC
2026-04-09DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-09DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-19SEC
2026-04-024Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-02-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-268-KCurrent report2026-02-26SEC
2026-02-23144Filing for proposed sale of securities under Rule 144.SEC
2026-02-234Statement of changes in beneficial ownership of securities2026-02-20SEC
2026-02-234Statement of changes in beneficial ownership of securities2026-02-20SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-081.03M300
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-0200100.24K10
2026-012.08M315.87K5
2025-120000
2025-11002.29K5

Institutional holders

Manager% owned
AIGH Capital Management LLC6.50%
Soleus Capital Management, L.P.5.66%
Telemark Asset Management, LLC5.12%
Birchview Capital, LP2.77%
VANGUARD CAPITAL MANAGEMENT LLC2.74%
Aberdeen Group plc2.73%
ESSEX INVESTMENT MANAGEMENT CO LLC2.22%
Opaleye Management Inc.1.74%
MARSHALL WACE, LLP1.12%
PERCEPTIVE ADVISORS LLC1.05%

Funds

Fund% owned
abrdn Healthcare Opportunities Fund3.82%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.97%
VANGUARD EXTENDED MARKET INDEX FUND0.70%
1290 Essex Small Cap Growth Fund0.57%
Fidelity Extended Market Index Fund0.28%
iShares Micro-Cap ETF0.17%
Ultra-Small Company Fund0.14%
Fidelity Total Market Index Fund0.11%
Ultra-Small Company Market Fund0.10%
Fidelity Series Total Market Index Fund0.09%

OakChart. BDSX. Cached 15 minutes.